Cristina Alonso

List of Publications by Year
in descending order

30 papers	**1,730** citations	361296 **20** h-index	501076 **28** g-index
32 all docs	**32** docs citations	**32** times ranked	**2753** citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. Journal of Hepatology, 2022, 77, 15-28.	1.8	31
2	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31
3	A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. Journal of Hepatology, 2022, 76, 800-811.	1.8	15
4	The Lâ€Ì±â€Lysophosphatidylinositol/G Proteinâ€"Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis. Hepatology, 2021, 73, 606-624.	3.6	42
5	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 835-856.	8.2	183
6	Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer. Cancers, 2021, 13, 6216.	1.7	16
7	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl4-Induced Liver Fibrosis. International Journal of Molecular Sciences, 2020, 21, 9043.	1.8	12
8	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International, 2020, 40, 2860-2876.	1.9	12
9	Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers, 2020, 12, 1142.	1.7	53
10	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1433.	1.7	20
11	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 2020, 12, 1644.	1.7	38
12	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. Cell Metabolism, 2020, 31, 605-622.e10.	7.2	68
13	Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. Hepatology Communications, 2020, 4, 193-207.	2.0	15
14	Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology, 2020, 159, 999-1014.e9.	0.6	59
15	Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2019, 25, 3009-3020.	1.4	115
16	Emerging Circulating Biomarkers for TheÂDiagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. , 2019, , 423-448.		4
17	Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c. , 2019, , 405-421.		0
18	Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development, 2019, 4, 283-297.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	3.6	112
20	Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 1702-1709.	2.2	39
21	Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice. Hepatology Communications, 2018, 2, 1513-1532.	2.0	49
22	The fatty acids of sphingomyelins and ceramides in mammalian tissues and cultured cells: Biophysical and physiological implications. Chemistry and Physics of Lipids, 2018, 217, 29-34.	1.5	26
23	Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer. Cancers, 2018, 10, 300.	1.7	18
24	Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology Communications, 2018, 2, 807-820.	2.0	117
25	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology, 2017, 152, 1449-1461.e7.	0.6	209
26	Role of aramchol in steatohepatitis and fibrosis in mice. Hepatology Communications, 2017, 1, 911-927.	2.0	84
27	Enhancing metabolomics research through data mining. Journal of Proteomics, 2015, 127, 275-288.	1.2	87
28	Deciphering non-alcoholic fatty liver disease through metabolomics. Biochemical Society Transactions, 2014, 42, 1447-1452.	1.6	26
29	Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology, 2013, 58, 1296-1305.	3.6	100
30	Liquid Chromatographyˆ˜Mass Spectrometry-Based Parallel Metabolic Profiling of Human and Mouse Model Serum Reveals Putative Biomarkers Associated with the Progression of Nonalcoholic Fatty Liver Disease. Journal of Proteome Research, 2010, 9, 4501-4512.	1.8	144